Dr. Bhatia commented that the most important clinical consideration is which treatment strategy is likely to offer the best relapse-free survival.
"Then we have the luxury of looking at whether we have a mode of therapy that is less toxic down the road," she said.
The study was supported in part by the Leukemia & Lymphoma Society. Dr. Bhatia and Dr. Miller reported having no relevant conflicts of interest to disclose.